Cargando…

Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer

PURPOSE: This study aimed to detect the expression levels of topoisomerase IIα (TOP2A), ribonucleotide reductase catalytic subunit M1 (RRM1),c-erbB-2 (HER2) and excision repair cross complementing group 1 (ERCC1) in non-muscular invasive bladder cancer (NMIBC) and explore the correlation between the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhifei, Xing, Liyong, Zhu, Yanfeng, Shi, Peng, Deng, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194599/ https://www.ncbi.nlm.nih.gov/pubmed/35711974 http://dx.doi.org/10.1016/j.heliyon.2022.e09643

Ejemplares similares

Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study
por: Li, Juncheng, et al.
Publicado: (2021)

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
por: Valsecchi, Matias E, et al.
Publicado: (2012)

The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes
por: Kim, Dokyung, et al.
Publicado: (2011)

Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis
por: YU, YONGKANG, et al.
Publicado: (2014)

The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
por: Wahba, Nagwa Ismail, et al.
Publicado: (2023)

Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer
por: Cao, Yongkuan, et al.
Publicado: (2017)

Predictive and Prognostic Significance of mRNA Expression and DNA Copies Aberrations of ERCC1, RRM1, TOP1, TOP2A, TUBB3, TYMS, and GSTP1 Genes in Patients with Breast Cancer
por: Tsyganov, Matvey M., et al.
Publicado: (2022)

Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
por: Tsyganov, Matvey M., et al.
Publicado: (2022)

ERCC1、RRM1和TS在非小细胞肺癌中的临床意义
Publicado: (2014)

Relevance of ERCC1, RRM1 and BRCA1 in surgically treated non-small cell lung cancer patients
por: Pesta, Martin, et al.
Publicado: (2014)

Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer
por: Jian-wei, Bi, et al.
Publicado: (2013)

ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy
por: Qiao, Hongwei, et al.
Publicado: (2014)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development
por: Rouissi, Kamel, et al.
Publicado: (2011)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma
por: Cui, Qing-ke, et al.
Publicado: (2014)

The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival
por: Tantraworasin, Apichat, et al.
Publicado: (2013)

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population
por: Liu, Dabiao, et al.
Publicado: (2018)

Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients
por: Grenda, Anna, et al.
Publicado: (2019)

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy
por: Leng, Xue-Feng, et al.
Publicado: (2012)

Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1
por: Li, Jingyao, et al.
Publicado: (2021)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer
por: Li, Yilun, et al.
Publicado: (2022)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer
por: GÓMEZ-DÍAZ, BENJAMÍN, et al.
Publicado: (2015)

Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis
por: Zhang, Haiguang, et al.
Publicado: (2017)

Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer
por: Tóth, Csaba, et al.
Publicado: (2017)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
por: Nicoś, Marcin, et al.
Publicado: (2020)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
por: Zhang, Keqiang, et al.
Publicado: (2009)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

ERCC1 and ERCC2 Haplotype Modulates Induced BPDE-DNA Adducts in Primary Cultured Lymphocytes
por: Lu, Xiaobo, et al.
Publicado: (2013)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia
por: Chatzidavid, Sevastianos, et al.
Publicado: (2023)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy
por: Kawashima, Atsunari, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rcn40antaqs6j29n4c0682vuch